New combo therapy aims to boost immune attack on kidney cancer

NCT ID NCT03092856

Ongoing Disease control Sponsor: University of Southern California Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding an experimental drug (PF-04518600) that boosts the immune system to the standard drug axitinib can help control advanced kidney cancer better than axitinib alone. About 62 adults whose cancer has spread and who have already tried an immune checkpoint inhibitor will take part. The main goal is to see if the combination delays cancer growth.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nonpapillary renal cell carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLEAR CELL RENAL CELL CARCINOMA METASTATIC RENAL CELL CANCER RECURRENT RENAL CELL CARCINOMA STAGE IV RENAL CELL CANCER

Contacts and locations

Locations

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center

Cleveland, Ohio, 44195, United States
Los Angeles County-USC Medical Center

Los Angeles, California, 90033, United States
USC / Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States
USC Norris Oncology/Hematology-Newport Beach

Newport Beach, California, 92663, United States
University of California Davis Comprehensive Cancer Center

Sacramento, California, 95817, United States
University of Kansas Cancer Center

Kansas City, Kansas, 66160, United States
University of Pittsburgh Cancer Institute (UPCI)

Pittsburgh, Pennsylvania, 15232, United States
University of Virginia Cancer Center

Charlottesville, Virginia, 22903, United States
Weill Cornell Medical College, New York- Presbyterian Hospital

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.